
Karuna Therapeutics KRTX
Annual report 2023
added 02-22-2024
Karuna Therapeutics General and Administrative Expenses 2011-2026 | KRTX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 76.1 M | 52.6 M | 28.4 M | 20.9 M | 2.97 M | 1.19 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 131 M | 1.19 M | 44.8 M |
Quarterly General and Administrative Expenses Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.3 M | 27.4 M | 24.3 M | - | 19.1 M | 17.8 M | 14.8 M | - | 12.4 M | 10.4 M | 9.78 M | - | 6.94 M | 7.01 M | 5.64 M | - | 4.1 M | 8.29 M | 4.61 M | - | 1.06 M | 256 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.3 M | 256 K | 12.1 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.83 | 2.17 % | $ 4.53 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
BioNTech SE
BNTX
|
286 M | $ 110.14 | 3.3 % | $ 27.2 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
14.4 M | $ 2.6 | -1.12 % | $ 146 M | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.51 | -0.52 % | $ 8.45 B | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 4.21 | 1.2 % | $ 9.16 B | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
100 M | $ 1.49 | 7.19 % | $ 279 M | ||
|
Aptose Biosciences
APTO
|
11.2 M | - | -45.71 % | $ 1.2 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 221.8 | -0.16 % | $ 5 B | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
7.16 M | - | 17.91 % | $ 11.1 M | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 8.96 | 0.45 % | $ 1.41 B | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Athira Pharma
ATHA
|
26.1 M | - | - | $ 269 M | ||
|
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.46 | 2.46 % | $ 373 M | ||
|
Amneal Pharmaceuticals
AMRX
|
476 M | $ 14.49 | -0.24 % | $ 4.48 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
17.4 M | $ 2.35 | -1.81 % | $ 14.8 M | ||
|
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | ||
|
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M |